My best friend lives with Multiple Sclerosis (MS), and I have seen firsthand how crucial the treatments Ocrevus and Kesimpta are in maintaining their health, independence, and quality of life. For them, these medications are not just treatments; they are lifelines that stop this unpredictable disease from taking away their future.

The Australian government plans to remove these high-efficacy medications from the Pharmaceutical Benefits Scheme (PBS), which would have dire consequences for thousands of Australians living with MS. If this proposal goes through, people like my friend will lose affordable access to treatments that significantly halt disease progression and improve their lives.

According to the MS Research Australia, approximately 25,600 Australians live with MS, a chronic neurological disease that affects the central nervous system. Ocrevus and Kesimpta have been proven to drastically reduce relapse rates and slow the progression of disability. By removing these medications from the PBS, the government risks exacerbating the financial, physical, and emotional burdens felt by MS patients and their families.

The financial barrier posed by this decision means that only those who can afford the exorbitant out-of-pocket costs will continue to access these vital treatments. The average cost of MS medication without PBS support can reach up to tens of thousands of dollars per year, putting them out of reach for many.

We cannot let financial cuts compromise the vital healthcare that ensures a meaningful quality of life for those battling MS. These treatments are essential for maintaining health and independence, helping individuals stay employed, support their families, and contribute to society.

Please join me in advocating for the preservation of these crucial medications on the PBS. Your signature can make a difference in securing the future and well-being of thousands living with MS.

Sign the petition today to stand up for the MS community and demand Ocrevus and Kesimpta remain on the PBS.